Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125432901 | 12543290 | 1 | I | 20160601 | 20160711 | 20160711 | EXP | TW-ROCHE-1787091 | ROCHE | YANG C, LEE C-Y, YEH C-C AND TSAI M-K. RENAL TRANSPLANTATION ACROSS THE DONOR SPECIFIC ANTIBODY BARRIER: GRAFT OUTCOME AND CANCER RISK AFTER DESENSITIZATION THERAPY. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION 2016;115:426-433. | 0.00 | Y | 0.00000 | 20160711 | OT | TW | TW |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125432901 | 12543290 | 1 | PS | Rituximab | RITUXIMAB | 1 | Intravenous (not otherwise specified) | U | 103705 | SOLUTION FOR INFUSION | |||||||||
| 125432901 | 12543290 | 2 | SS | MYCOPHENOLATE MOFETIL. | MYCOPHENOLATE MOFETIL | 1 | Unknown | U | 50722 | ||||||||||
| 125432901 | 12543290 | 3 | SS | MYCOPHENOLATE MOFETIL. | MYCOPHENOLATE MOFETIL | 1 | U | 50722 | |||||||||||
| 125432901 | 12543290 | 4 | SS | TACROLIMUS. | TACROLIMUS | 1 | Unknown | U | 0 | ||||||||||
| 125432901 | 12543290 | 5 | SS | TACROLIMUS. | TACROLIMUS | 1 | U | 0 | |||||||||||
| 125432901 | 12543290 | 6 | SS | METHYLPREDNISOLONE. | METHYLPREDNISOLONE | 1 | Intravenous (not otherwise specified) | U | 0 | ||||||||||
| 125432901 | 12543290 | 7 | SS | METHYLPREDNISOLONE. | METHYLPREDNISOLONE | 1 | U | 0 | |||||||||||
| 125432901 | 12543290 | 8 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | U | 0 | ||||||||||
| 125432901 | 12543290 | 9 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | U | 0 | |||||||||||
| 125432901 | 12543290 | 10 | C | IVIG | HUMAN IMMUNOGLOBULIN G | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125432901 | 12543290 | 1 | Prophylaxis against transplant rejection |
| 125432901 | 12543290 | 2 | Immunosuppression |
| 125432901 | 12543290 | 3 | Prophylaxis against transplant rejection |
| 125432901 | 12543290 | 4 | Immunosuppression |
| 125432901 | 12543290 | 5 | Prophylaxis against transplant rejection |
| 125432901 | 12543290 | 6 | Immunosuppression |
| 125432901 | 12543290 | 7 | Prophylaxis against transplant rejection |
| 125432901 | 12543290 | 8 | Immunosuppression |
| 125432901 | 12543290 | 9 | Prophylaxis against transplant rejection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125432901 | 12543290 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125432901 | 12543290 | Colon cancer | |
| 125432901 | 12543290 | Endometrial cancer | |
| 125432901 | 12543290 | Pneumocystis jirovecii pneumonia | |
| 125432901 | 12543290 | Pneumonia bacterial | |
| 125432901 | 12543290 | Pneumonia viral | |
| 125432901 | 12543290 | Polyomavirus-associated nephropathy | |
| 125432901 | 12543290 | Thyroid cancer | |
| 125432901 | 12543290 | Transitional cell carcinoma | |
| 125432901 | 12543290 | Tuberculosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |